CTIS2022-500570-33-00招募中1 期
A Randomised, Open Label, Phase III, Multicenter, 2-arm study comparing 177Lu-PSMA-I&T versus Apalutamide/Enzalutamide/Abiraterone, in metastatic Hormon Sensitive Prostate Cancer Patients receiving castration treatment - Lut-AEA
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 844
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- Male
入选标准
- •Histological or cytological proven prostate adenocarcinoma, Metastatic HSPC with measurable or evaluable disease, Patients must have evidence of PSMA-positive disease as seen on a [18F]PSMA-1007 or [68]Ga-gozetotide PET/CT scan, Patients included in the study that have fertile female partners must use adequate contraception, i.e. condom, within their relationship from start of the trial until 3 months after the last dose, Age = 18 years, ECOG 0- 2, Estimated survival = 3 months, Not eligible for triple therapy with Docetaxel, WBC 2000/mm3, neutrophils =1500/mm3, platelets =100,000/mm3, Satisfactory liver function: bilirubin, transaminases = 1.5 times the upper limit of normal., Satisfactory renal function: Serum creatinine <1.5 x ULN (150 mmol/l). If creatinine 1.0 – 1.5 x ULN, creatinine clearance will be calculated according to CKD-EPI formula and patients with creatinine clearance >60 mL/min are accepted in the study. (For calculation see https://www.qxmd.com/calculate-online/nephrology/ckd-epi-egfr), Patient information and signature of informed consent
排除标准
- •Cardiovascular disease (severe symptomatic coronary artery disease, congenital heart failure, class 3 and 4 of the NYHA), Prior treatment with second generation anti-androgen, Prior treatment with chemotherapy, Prior treatment with radiopharmaceutical agents for prostate cancer, Uncontrolled severe illness or medical condition (including uncontrolled diabetes mellitus), Concurrent treatment with drugs decreasing the seizure threshold and/or cause seizure, Uncontrolled hypertension (systolic bloodpressure >160 mmHg or diastolic blood pressure >100 mmHg), Subjects with hypersensitivity or contraindications to Apalutamide, Enzalutamide and/or Abiraterone acetate, according to the SmPC, should not be included in the study., Inadequate organ and bone marrow function as evidenced by: Hemoglobin <10.0 g/dL Absolute neutrophil count <1.5 x 10^9/L, Platelet count <100 x 10^9/L, AST and/or ALT >1.5 x ULN; Total bilirubin >1.5 x ULN, Serum creatinine >1.5 x ULN. If creatinine 1.0 - 1.5 x ULN, creatinine clearance will be calculated according to CKD-EPI formula and patients with creatinine clearance <60 mL/min should be excluded (see http://www.qxmd.com/calculate-online/nephrology/ckd-epi-egfrfor for calculation), Active infection or other serious underlying pathology that could prevent patients from receiving treatment, History of cancer within 5 years before inclusion in the study other than basal cell or squamous cell skin cancer adequately treated, Brain metastases, uncontrolled symptomatic or asymptomatic, Patient participating in another clinical trial protocol with a molecule during this experimental study or treated four weeks prior to randomization., Systemic treatment with high dose steroids, Any severe acute or chronic medical condition which would impair the ability of the patient to participate to the study or interfere with interpretation of study results, or patient unable to comply with the study procedures., Prior treatment with ADT, Bicalutamide or Abiraterone acetate
研究者
相似试验
进行中（未招募）
1 期
A Randomized, Open Label, Phase III, Multicenter, 2-Arm Study of Androgen deprivation +/- Taxotere? (Docetaxel) for Non metastatic Prostate Cancer Patients with a Rising PSA. - PSA-ERECTPatients with prostate cancer.The study will include two patient cohorts, which at inclusion has a similar risk for progression of the disease at 5 years, and risk of later prostate cancer death. The first patient group are patients with PSA relapse after curative treatment, and the 2nd one are patients with locally advanced disease.MedDRA version: 9.1Level: LLTClassification code 10036910Term: Prostate cancer NOSEUCTR2008-003138-33-FIScandinavian Prostate Cancer Group (SPCG)430
招募中
3 期
A Randomized, Open Label, Phase III, Multicenter, 2-Arm Study of Androgen deprivation +/- Taxoterere* (Docetaxel) for Non metastatic Prostate Cancer Patients with a Rising PSA.prostate carcinoma1003858810036958Prostate cancerNL-OMON35597Scandinavian Prostate Cancer Group20
进行中（未招募）
1 期
A Randomized, Open Label, Phase III, Multicenter, 2-Arm Study of Androgen deprivation +/- Taxotere? (Docetaxel) for Non metastatic Prostate Cancer Patients with a Rising PSA.Patients with prostate cancer.The study will include two patient cohorts, which at inclusion has a similar risk for progression of the disease at 5 years, and risk of later prostate cancer death. The first patient group are patients with PSA relapse after curative treatment, and the 2nd one are patients with locally advanced disease.EUCTR2008-003138-33-DKScandinavian Prostate Cancer Group (SPCG)430
进行中（未招募）
1 期
A Randomized, Open Label, Phase III, Multicenter, 2-Arm Study of Androgen deprivation +/- Taxotere? (Docetaxel) for Non metastatic Prostate Cancer Patients with a Rising PSA. - SPCG 14Patients with prostate cancer.The study will include two patient cohorts, which at inclusion has a similar risk for progression of the disease at 5 years, and risk of later prostate cancer death. The first patient group are patients with PSA relapse after curative treatment, and the 2nd one are patients with locally advanced disease.EUCTR2008-003138-33-SEScandinavian Prostate Cancer Group (SPCG)430
进行中（未招募）
1 期
A Randomized, Open Label, Phase III, Multicenter, 2-Arm Study of Androgen deprivation +/- Taxotere? (Docetaxel) for Non metastatic Prostate Cancer Patients with a Rising PSA. - PSA-ERECTPatients with prostate cancer.The study will include two patient cohorts, which at inclusion have a similar risk for progression of the disease at 5 years, and risk of later prostate cancer death. The first patient group are patients with PSA relapse after curative treatment, and the 2nd one are patients with locally advanced disease.EUCTR2008-003138-33-NLScandinavian Prostate Cancer Group (SPCG)430